Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

417 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma.
Pashenkov M, Goëss G, Wagner C, Hörmann M, Jandl T, Moser A, Britten CM, Smolle J, Koller S, Mauch C, Tantcheva-Poor I, Grabbe S, Loquai C, Esser S, Franckson T, Schneeberger A, Haarmann C, Krieg AM, Stingl G, Wagner SN. Pashenkov M, et al. Among authors: stingl g. J Clin Oncol. 2006 Dec 20;24(36):5716-24. doi: 10.1200/JCO.2006.07.9129. J Clin Oncol. 2006. PMID: 17179105 Clinical Trial.
Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination.
Maass G, Schmidt W, Berger M, Schilcher F, Koszik F, Schneeberger A, Stingl G, Birnstiel ML, Schweighoffer T. Maass G, et al. Among authors: stingl g. Proc Natl Acad Sci U S A. 1995 Jun 6;92(12):5540-4. doi: 10.1073/pnas.92.12.5540. Proc Natl Acad Sci U S A. 1995. PMID: 7777545 Free PMC article.
Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene.
Stingl G, Brŏcker EB, Mertelsmann R, Wolff K, Schreiber S, Kămpgen E, Schneeberger A, Dummer W, Brennscheid U, Veelken H, Birnstiel ML, Zatloukal K, Schmidt W, Maass G, Wagner E, Baschle M, Giese M, Kempe ER, Weber HA, Voigt T. Stingl G, et al. Hum Gene Ther. 1996 Mar 1;7(4):551-63. doi: 10.1089/hum.1996.7.4-551. Hum Gene Ther. 1996. PMID: 8800750 Clinical Trial. No abstract available.
Phase I study to the immunotherapy of metastatic malignant melanoma by a cancer vaccine consisting of autologous cancer cells transfected with the human IL-2 gene.
Stingl G, Bröcker EB, Mertelsmann R, Wolff K, Schreiber S, Kämpgen E, Schneeberger A, Trcka J, Brennscheidt U, Veelken H, Birnstiel ML, Zatloukal K, Maass G, Wagner E, Buschle M, Kempe ER, Weber HA, Voigt T. Stingl G, et al. J Mol Med (Berl). 1997 Apr;75(4):297-9. doi: 10.1007/s001090050115. J Mol Med (Berl). 1997. PMID: 9151216 Clinical Trial. No abstract available.
Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: outcome of a phase I study.
Schreiber S, Kämpgen E, Wagner E, Pirkhammer D, Trcka J, Korschan H, Lindemann A, Dorffner R, Kittler H, Kasteliz F, Küpcü Z, Sinski A, Zatloukal K, Buschle M, Schmidt W, Birnstiel M, Kempe RE, Voigt T, Weber HA, Pehamberger H, Mertelsmann R, Bröcker EB, Wolff K, Stingl G. Schreiber S, et al. Among authors: stingl g. Hum Gene Ther. 1999 Apr 10;10(6):983-93. doi: 10.1089/10430349950018382. Hum Gene Ther. 1999. PMID: 10223732 Clinical Trial.
417 results